European Commission approves ‘next-generation’ Covid-19 booster vaccine

European Commission approves 'next-generation' COVID-19 booster vaccine

European Commission approves 'next-generation' COVID-19 booster vaccine. Credit: Komsan Loonprom/

THE European Commission has announced that it has approved a ‘next-generation’ Covid-19 booster vaccine.

Sanofi and GSK’s new jab, which is VidPrevtyn Beta, is the only next-generation protein-based adjuvanted Covid booster approved in Europe.

Experts say it has shown a “strong immune response against all tested variants of concern” across several studies and will be ready to supply for winter vaccination campaigns in Europe for those aged 18 and over.

The same recombinant-protein technology is used in Sanofi’s approved seasonal flu vaccines.

One study’s results showed a 64.7 per cent efficacy against symptomatic SARS-CoV-2 infection in adults, regardless of their infection status prior to vaccination, and 75.1 per cent efficacy in participants previously infected with the virus.

This study, named VAT08 Stage 2 Efficacy & Safety, was the first ever to report efficacy data in an Omicron environment.

In another study, VAT02 cohort 2 study, reactions were “mostly mild to moderate, transient and self resolutive”.

The European Medicines Agency says that vaccines “protect against severe disease and hospitalisation caused by Omicron variant, especially in people who have had a booster dose”.

The European Commission will now fast-track the decision-making process to grant a decision on the standard marketing authorisation for VidPrevtyn Beta, allowing this vaccine to be included in vaccination programmes rolled out across the EU.

Thomas Triomphe, executive vice president of vaccines at Sanofi, said: “Today’s approval validates our research in developing a novel solution for the COVID-19 pandemic.

“As we’re ready to start first shipments, VidPrevtyn Beta will be an important new option to protect populations against multiple strains of COVID-19.”

Philip Dormitzer, global head of research and development vaccines, at GSK “This EC approval is an important step in providing further vaccine solutions to Europe for the coming winter.

“Our protein-based, adjuvanted vaccine candidate has the potential to make an important contribution to public health as the pandemic evolves further.”

Thank you for taking the time to read this article, do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.

Vickie S
Written by

Vickie Scullard

A journalist of more than 12 years from Manchester, UK, Vickie now lives in Madrid and works as a news writer for the Euro Weekly News.


    • Dr Trth

      11 November 2022 • 18:25

      As they say you can stick it! if people are silly enough “even now” to believe this vaccine nonsense, think people – think! your life expectancy will be reduced or maybe we will see your name up here one day.

    Comments are closed.